article thumbnail

FTC order could ease biopharma competition

European Pharmaceutical Review

to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.

article thumbnail

UK life science competitiveness indicators 2022: measuring what matters most?

pharmaphorum

The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. The 2022 LSCIs don’t, however, include the speed and volume of NICE Technology Appraisals that were in previous iterations. The July 2022 LSCIs are the eighth version. The life sciences ecosystem.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biosimilar competition saves US healthcare $21 billion

European Pharmaceutical Review

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. A rise in savings per quarter was recognised in this year’s data.

article thumbnail

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Pharmaceutical Technology

Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month In addition to Enhertu, Trodelvy may also experience competition from Daiichi/AstraZeneca’s anti-TROP2 ADC, datopotamab deruxtecan (dato-DXd), which is being investigated in the Phase III TROPION-Breast01 trial for previously treated HR+/HER2- patients.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Avadel Pharmaceuticals developed Lumryz, a sodium oxybate that is a once-daily, extended-release oral suspension that gained tentative FDA approval in July 2022. Competition starts to heat up. Classic treatment options. Xyrem is one of three that has a patent. About the author.

article thumbnail

Moderna’s Covid-19 vaccine sales forecast slashed amidst strong competition

Pharmaceutical Technology

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.

article thumbnail

How payers can use price transparency as a competitive advantage 

Clarify Health

Since July 2022, CMS has required most group health plans and issuers of group or individual health insurance to post price information for covered items and health services. For most, the concept of price transparency has been approached as a compliance necessity. However, it offers far more than just adherence to regulations.